Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°Ç°­ °ËÁø¿¡¼­ ½ÃÇàµÈ Àü¸³¼±Æ¯ÀÌÇ׿ø °Ë»ç¿¡ ´ëÇÑ ¿¬·Éº° ÂüÁ¶¹üÀ§ Age-specific Reference Ranges for Prostate Specific Antigen from a Health Center in Korea

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 5È£ p.583 ~ 588
ÀÌÅ°æ, Á¤Å±Ô, ÀÓÁ¤±æ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÅ°æ (  ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Á¤Å±Ԡ(  ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
ÀÓÁ¤±æ (  ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
Àü¸³¼±¾ÏÀº 1996³âµµ¿¡ ½ÃÇàµÈ Á¶»ç¿¡ µû¸£¸é ¹Ì±¹¿¡¼­ ¸Å³â 317,000¸íÀÇ »õ·Î¿î ȯÀÚ°¡
¹ß»ýÇÏ°í 41,000¸íÀÌ »ç¸ÁÇÏ°í ÀÖ´Â, ÇöÀç ¹Ì±¹ ³²¼º¿¡ À־ °¡Àå ¸¹Àº ¾ÏÀ̸ç, µÎ¹ø°ÀÇ
»ç¸Á¿øÀÎÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
Àü¸³¼±Æ¯ÀÌÇ׿øÀº Àü¸³¼±¿¡ ƯÀÌÇÏ´Ù°í ¾Ë·ÁÁø 1979³â ÀÌ·¡ ÇöÀç±îÁö Àü¸³¼±¾ÏÀÇ Áø´Ü°ú
Ä¡·áÀÇ ÃßÀû °Ë»ç¿¡ ÀÖ¾î °¡Àå À¯¿ëÇÑ Á¾¾çÇ¥ÁöÀÚ·Î »ç¿ëµÇ¾î ¿Ô´Ù. ±×·¯³ª ÀÌ Àü¸³¼±Æ¯ÀÌ
Ç׿øÀÇ ³óµµ´Â ±Þ¼º´¢Æó, Àü¸³¼±¿°, Àü¸³¼±ÀÇ ÇãÇ÷ ¶Ç´Â °æ»ö, ¾ç¼ºÀü¸³¼±ºñ´ëÁõ°ú °°Àº ¾ç
¼º Áúȯ¿¡¼­µµ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¸ç ¸¹Àº ¿¬±¸Àڵ鿡 ÀÇÇØ ¿¬·É¿¡ µû¶ó ±× ³óµµ°¡ Áõ°¡ÇÑ´Ù´Â
°ÍÀÌ ¹àÇôÁ³´Ù.
Àü¸³¼±¾Ï°ú ¾ç¼ºÀü¸³¼±ºñ´ëÁõÀ» ±¸ºÐÇϴµ¥ ÀÖ¾î, Àü¸³¼±Æ¯ÀÌÇ׿øÀÇ Á¤»óÄ¡ÀÇ »óÇѼ±Àº
Tandem-R PSA assay¿¡ ÀÇÇÏ¿© 4.0ng/§¢·Î ¾Ë·ÁÁ® ¿Ô°í À̸¦ ±âÁØÀ¸·Î ÇÏ¿´À» ¶§ ¹Î°¨µµ
´Â 71%À̳ª ƯÀ̵µ´Â 49%ÀÇ °ªÀ» °¡Áö¸ç ÀÌ Æ¯À̵µ¸¦ ³ôÀ̱â À§ÇÏ¿© Àü¸³¼±Æ¯ÀÌÇ׿ø ¹Ðµµ
(PSAD), Àü¸³¼±Æ¯ÀÌÇ׿ø ¼Óµµ(PSA Velocity) µîÀÇ ¹æ¹ýÀÌ ¿¬±¸µÇ¾î ¼ÒÁ¤ÀÇ È¿°ú´Â º¸°í ÀÖ
À¸³ª °³°³Àκ° Â÷ÀÌ¿¡ µû¸¥ º¯ÀÌ·Î ÀÎÇØ ±× »ç¿ëÀÌ Á¦Çѵǰí ÀÖ´Ù. ÀÌ·¯ÇÑ Á¦ÇÑÀÇ ±Øº¹À»
À§ÇØ ÀÓ»óÀûÀ¸·Î Àü¸³¼±¾ÏÀÌ ¾ø´Â °æ¿ì¿¡µµ Á¤»óÀûÀ¸·Î ¿¬·É¿¡ µû¶ó Áõ°¡ÇÏ´Â Ç÷û Àü¸³¼±
ƯÀÌÇ׿øÀÇ Æ¯¼ºÀ» ¹Ý¿µÇÏ¿© ¿¬·É¿¡ µû¸¥ Ç÷û Àü¸³¼±Æ¯ÀÌÇ׿øÀÇ ÂüÁ¶¹üÀ§°¡ Á¦¾ÈµÇ¾ú´Ù.
ÀÌ Àü¸³¼±Æ¯ÀÌÇ׿ø¿¡ ´ëÇÑ ¿¬·Éº° ÂüÁ¶¹üÀ§´Â ¿©·¯ ¿¬±¸Àڵ鿡 ÀÇÇØ Á¶»çµÇ¾úÀ¸¸ç ¼­±¸Àεé
ÀÇ ÂüÁ¶¹üÀ§´Â Àß ¾Ë·ÁÁ® ÀÖ´Ù. ¿ì¸® Çѱ¹ÀÎ ³²¼ºÀº ÀϹÝÀûÀ¸·Î ¼­±¸Àε鿡 ºñÇÏ¿© Àü¸³¼±
¾ÏÀÇ ¹ß»ý·üÀÌ ³·°í Àü¸³¼±ÀÇ Å©±âµµ ÀÛÀ¸¸ç Æò±ÕÀûÀ¸·Î Ç÷û Àü¸³¼± ƯÀÌÇ׿ø ¼öÄ¡µµ ³·Àº
°ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸³ª, µ¿¾çÀο¡¼­ÀÇ ¿¬±¸´Â ÀϺ»ÀÎÀ» ´ë»óÀ¸·Î ÇÏ¿´´ø ¿¬±¸°¡ À¯ÀÏÇϸç, ¿ì
¸®³ª¶ó ³²¼ºÀÇ Àü¸³¼±Æ¯ÀÌÇ׿øÄ¡¿¡ ´ëÇÑ ±¤¹üÀ§ÇÏ°í ü°èÀûÀÎ ¿¬±¸´Â °ÅÀÇ Àü¹«ÇÑ ½ÇÁ¤ÀÌ
´Ù. º» ¿¬±¸¿¡¼­´Â ºñ·Ï ÇÑ ÀÇ·á±â°ü¿¡¼­ ½ÃÇàµÇ¾úÁö¸¸ Çѱ¹Àο¡¼­ÀÇ Ç÷û Àü¸³¼±Æ¯ÀÌÇ׿ø
¼öÄ¡¿Í ±× °á°ú¸¦ Åä´ë·Î ¿¬·Éº° ÂüÁ¶¹üÀ§¸¦ ±¸ÇÏ¿© ³»±¹ÀÎÀÇ Áø·á¿¡ ÀÖ¾î ±× ±âÁØÄ¡¸¦ ¸¶
·ÃÇØ º¸°í, °Ç°­°ËÁø¿¡ Âü¿©ÇÏ¿´´ø »ç¶÷µéÀ» ´ë»óÀ¸·Î Çѱ¹³²¼ºµé¿¡ À־ÀÇ Àü¸³¼±¾ÏÀÇ
À¯º´·üÀ» Á¶»çÇØ º¸°íÇÑ´Ù.

Purpose : The PSA is believed to be the most useful tumor marker available for
prostate cancer. Several investigations were published which established the role of
age-specific reference ranges in screening and early detection of prostate cancer. This
study is to determine age-specific reference ranges for serum PSA concentration in a
health center of Korea in comparison with those of other races.
Materials and Methods : Between June, 1996 and May, 1997, a total of 18,928 Korean
men aged 40 to 79 years who were examined in the health center of Asan Medical
Center had serum PSA screening tests for prostate cancer. There were 9 cases of
prostate cancer. Serum PSA concentrations of whom had no prostate cancer were
determined with Tandem-R PSA assay(Hybritech). Descriptive statistics, including the
median values, 25th, 75th and 95th percentiles of the distribution of serum PSA
concentration, were calculated for 10-year age-groups from aged 40 through 79. A
regression model was used to characterize the distribution of the logarithm of serum
PSA concentration by age.
Results : The serum PSA concentration correlated directly with age(r=0.19; p<0.05).
Adjusted for age, the serum PSA concentration was lower for Korean men than for
Caucasian, black men or Japanese men. Thus the recommended age-specific reference
ranges(95th percentile) for serum PSA concentration for Korean men of our health
center were lower as well; 0.0-2.1ng/§¢ for 40-49 years, 0.0-2.5ng/§¢ for 50-59 years,
0.0-3.0ng/§¢ for 60-69 years, 0.0-3.6ng/§¢ for 70-79 years.
Conclusions : These findings suggest that the age-specific reference ranges for serum
PSA concentration are lower for Korean men than for Caucasian or black men. Newly
proposed age-specific reference ranges by our institute would be more valuable for
Korean men.

Å°¿öµå

PSA; Cufoff value; Age-specific reference range;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS